Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

F9813

Sigma-Aldrich

Fludarabine phosphate

Synonim(y):

2-Fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amine

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C10H13FN5O7P
Numer CAS:
Masa cząsteczkowa:
365.21
Kod UNSPSC:
51102829
NACRES:
NA.85

Formularz

powder

Poziom jakości

kolor

white

rozpuszczalność

DMSO: soluble

spektrum działania antybiotyku

neoplastics

Tryb działania

DNA synthesis | interferes

temp. przechowywania

−20°C

InChI

1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)

Klucz InChI

GIUYCYHIANZCFB-UHFFFAOYSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

Fludarabine is a purine analog included in the category of DNA-damaging drugs with well-known efficacy in B-cell chronic lymphocytic leukemia (B-CLL).

Zastosowanie


  • Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, Corynebacterium matruchotii, via Bioactivity-HiTES.: This study explores the interactions of clinical drugs like Fludarabine phosphate with Corynebacterium matruchotii, highlighting potential impacts on oral microbiota and implications for drug efficacy and safety (Lee DY et al., 2024).

  • Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours.: Investigates the efficacy of a combination of Fludarabine phosphate with other chemotherapeutics delivered via nanocarriers, aiming to enhance treatment outcomes for pancreatic cancer by improving drug delivery to the tumor site (Rudolph D et al., 2024).

  • Macrophage neogenin deficiency exacerbates myocardial remodeling and inflammation after acute myocardial infarction through JAK1-STAT1 signaling.: This research demonstrates the role of Fludarabine phosphate in modulating inflammation and cardiac repair post-myocardial infarction, offering insights into its potential therapeutic benefits beyond oncology (Zhang J et al., 2023).

  • SLC25A51 promotes tumor growth through sustaining mitochondria acetylation homeostasis and proline biogenesis.: Discusses the cellular mechanisms by which Fludarabine phosphate may influence metabolic pathways in cancer cells, highlighting its potential to disrupt tumor metabolism and promote cancer cell death (Li Y et al., 2023).

  • CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.: Reviews the use of Fludarabine phosphate in preconditioning regimens for CAR T-cell therapy, emphasizing its role in enhancing the efficacy of immunotherapy in treating autoimmune disorders (Pecher AC et al., 2023).


Działania biochem./fizjol.

Fludarabine represses DNA replication and suppresses the nucleotide metabolism by inhibiting the enzyme ribonucleotide reductase.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Piktogramy

Health hazard

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

Zwroty wskazujące środki ostrożności

Klasyfikacja zagrożeń

Muta. 2 - Repr. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Francesca Ricci et al.
Therapeutics and clinical risk management, 5(1), 187-207 (2009-05-14)
Fludarabine (FAMP) is the most effective and most extensively studied purine analog in indolent B-cell malignancies. Its use is indicated for first-and second-line treatment of B-cell chronic lymphocytic leukemia (B-CLL). FAMP as a single agent has produced superior response rates
Andrea Celeghin et al.
Cell death & disease, 7(12), e2562-e2562 (2016-12-30)
Besides its canonical role in stabilizing telomeres, telomerase reverse transcriptase (TERT) may promote tumorigenesis through extra-telomeric functions. The possible therapeutic effects of BIBR1532 (BIBR), a powerful TERT inhibitor, have been evaluated in different cellular backgrounds, but no data are currently
Míriam Molina-Arcas et al.
Blood, 101(6), 2328-2334 (2002-11-02)
Nucleoside derivatives are currently used in the treatment of hematologic malignancies. Although intracellular events involved in the pharmacologic action of these compounds have been extensively studied, the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in leukemia
W Plunkett et al.
Seminars in oncology, 17(5 Suppl 8), 3-17 (1990-10-01)
Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies. F-ara-A is transported into cells, where it is converted to its 5'-triphosphate
H M Kantarjian et al.
Seminars in oncology, 17(5 Suppl 8), 66-70 (1990-10-01)
The promising results obtained with Fludara I.V. (fludarabine phosphate) treatment in the common indolent B-cell neoplasms have led to their further evaluation in other unusual B-cell malignancies, in Hodgkin's disease, and in T-cell diseases. A significant response rate has been

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej